Skip to main content
Clinical Trials/NCT01284829
NCT01284829
Completed
Not Applicable

Performance of 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in the Diagnosis of Indeterminate Adrenal Tumors on Conventional Imaging: A French Prospective Multicentric Study

Assistance Publique Hopitaux De Marseille1 site in 1 country87 target enrollmentFebruary 4, 2011
ConditionsAdrenal Tumors

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Adrenal Tumors
Sponsor
Assistance Publique Hopitaux De Marseille
Enrollment
87
Locations
1
Primary Endpoint
diagnostic accuracy of FDG-PETparticularly the SUVmax tumor/liver ratio, in the diagnosis of indeterminate adrenal tumors on conventional imaging.
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This is a prospective study which aims to validate a new diagnostic approach in the tissue characterization of adrenal tumors indeterminate on conventional imaging. For this purpose, it is not necessary to have a control group since the diagnostic accuracy in a well defined subset of patients.

Visit 0 : Enrollment, eligibility. Visit 1 : FDG-PET. Visit 2 : Postoperative visit. Visit 3 : 6 months post-PET. Visit 4 : 12 months post-PET.

Detailed Description

Primary objective The primary objective is to assess the diagnostic accuracy of FDG-PET, particularly the SUVmax tumor/liver ratio, in the diagnosis of indeterminate adrenal tumors on conventional imaging. Secondary objectives * To assess the diagnostic accuracy of the tumor SUVmax, and SUVmax of the tumor/mean SUV of the liver. * To evaluate the relationship between SUVmax tumor/liver ratio and Weiss score. * To evaluate the impact of the use of FDG-PET on the treatment options. * To evaluate the economic impact of FDG-PET in the management of indeterminate adrenal tumors (ancillary study).

Registry
clinicaltrials.gov
Start Date
February 4, 2011
End Date
April 5, 2023
Last Updated
3 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adult ≥ 18 yrs, male or female;
  • Indeterminate adrenal tumor (6.3.1.). The CT must include the calculation of SD and contrast washout and should have been performed within the 30 days before the inclusion visit (visit 0) ;
  • Patient insured with public health care system ;
  • Patient who accept to participate to the study and to sign the consent document form.

Exclusion Criteria

  • Technical inability to perform FDG-PET.
  • Patient's death before final diagnosis.

Outcomes

Primary Outcomes

diagnostic accuracy of FDG-PETparticularly the SUVmax tumor/liver ratio, in the diagnosis of indeterminate adrenal tumors on conventional imaging.

Time Frame: 3 YEARS

Secondary Outcomes

  • assess the diagnostic accuracy of the tumorSUVmax, and SUVmax of the tumor/mean SUV of the liver.(3 YEARS)
  • To evaluate the impact of the use of FDG-PET on the treatment options(3 years)
  • To evaluate the relationship between SUVmax tumor/liver ratio and Weiss score(3 years)
  • To evaluate the economic impact of FDG-PET in the management of indeterminate adrenal tumors (ancillary study).(3 years)

Study Sites (1)

Loading locations...

Similar Trials